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The inflammatory hypothesis of depression is one of the main theories that endeavors to 
explain and describe the underlying biological mechanisms of depression and suicide. 
While mounting evidence indicates altered peripheral and central inflammatory profiles 
in depressed patients and suicide completers, little is known about how peripheral and 
central inflammation might be linked in these contexts. The choroid plexus (ChP), a 
highly vascularized tissue that produces cerebrospinal fluid (CSF) and lacks a blood–
brain–barrier, is an interface between peripheral and central immune responses. In the 
present study, we investigated the cellular and molecular inflammatory profile of the 
ChP of the lateral ventricle in depressed suicides and psychiatrically healthy controls. 
Gene expression of macrophages, pro- and anti-inflammatory cytokines, and various 
factors implicated in immune cell trafficking were measured; and density of ionized 
calcium-binding adaptor molecule 1-positive (Iba1+) macrophages associated with the 
ChP epithelial cell layer (ECL) was examined. Significant downregulations of the genes 
encoding interleukin 1ß (IL1ß), a pro-inflammatory acute-phase protein; intercellular cell 
adhesion molecule 1 (ICAM1), a protein implicated in immune cell trafficking in the ChP; 
and IBA1, a monocyte/macrophage marker; were detected in depressed suicides as 
compared to controls. No difference in the density of Iba1+ macrophages associated 
with the ChP ECL was observed. While interpretation of these findings is challenging 
in the absence of corroborating data from the CSF, peripheral blood, or brain paren-
chyma of the present cohort, we hypothesize that the present findings reflect a ChP 
compensatory mechanism that attenuates the detrimental effects of chronically altered 
pro-inflammatory signaling caused by elevated levels of pro-inflammatory cytokines, 
such as IL-1ß, peripherally and/or centrally. Together, these findings further implicate 
neuroimmune processes in the etiology of depression and suicide.
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introduction
Depression affects over 350 million people globally and is the 
leading cause of disability worldwide (1). Studies have consistently 
implicated mood disorders, including major depressive disorder 
(MDD), as a common factor underlying suicide. Approximately 
50% of children, adolescents, and adults who die by suicide have 
a prior mood disorder diagnosis, most commonly MDD (2, 3). 
Moreover, as many as 15% of individuals with a lifetime diagnosis 
of MDD admit to having attempted suicide at least once during 
their lives (4). As the relative contribution of depression to the 
global burden of disease increases, it becomes increasing impor-
tant to understand its biological underpinnings, as well as those 
of suicide, a global leading cause of death that claims the lives of 
more than 800,000 people annually (5).
The inflammatory hypothesis of depression is one of the main 
theories that endeavors to explain and describe the underlying 
biological mechanisms of depression and suicide outcomes. 
Originally termed the “Macrophage Theory of Depression,” 
(6) this hypothesis was first formulated based on observations 
of depressive symptoms precipitated by cytokine therapy in 
psychiatrically healthy, physically ill human patients [e.g., Ref. 
(7, 8)]. Maes et al. (9) later expanded this theory in the form of 
the “Monocyte-T-Lymphocyte Hypothesis of Depression.” A sub-
stantial number of studies have been undertaken to investigate 
the various aspects of this hypothesis, and a large literature has 
emerged in support of it.
Numerous animal studies have demonstrated that systemic or 
central administration of pro-inflammatory cytokines induces 
“sickness behavior,” a spectrum of behavioral signs of sickness, 
which overlap in large part with the behavioral symptoms of 
depressive-like states in animals (10, 11). In humans, suicide 
attempts and completions precipitated by cytokine therapy in 
psychiatrically healthy, physically ill patients have been reported 
(12). In addition, human populations suffering from chronic 
inflammatory conditions, such as type II diabetes, rheumatoid 
arthritis, and cardiovascular disease, have been reported to show 
increased incidences of depressive disorders (13). Furthermore, 
studies measuring peripheral expression of cytokines in depressed 
human patients have indicated that levels of pro-inflammatory 
cytokines, such as tumor necrosis factor alpha (TNF-α), inter-
leukin 1 beta (IL-1ß), and interleukin 6 (IL-6), are significantly 
higher in this clinical population compared to controls [(14–16); 
for meta-analyses, see Ref. (17–19)]. Interestingly, one study has 
further indicated that depressed patients who attempt suicide, 
more specifically, present elevated peripheral levels of pro-
inflammatory cytokines TNF-α and IL-6 (20).
Comparatively few studies have investigated inflammatory 
phenomena in the brain within the context of depression and 
suicide. Independent groups have reported evidence of increased 
pro-inflammatory cytokine expression in cortical regions impli-
cated in depression and suicide (21, 22). Furthermore, cellular 
evidence of increased immune activity in these brain areas has also 
been provided by our group and others (23–26). How peripheral 
and central inflammatory phenomena are linked in depression 
and suicide is a question that requires further investigation.
Several groups have investigated the relationship between 
cerebrospinal fluid (CSF) and peripheral (blood) cytokine 
expression in depressed patients and/or suicide attempters [e.g., 
Ref. (27, 28)]. While these studies provide divergent results with 
respect to CSF pro-inflammatory cytokine expression in patients 
versus control subjects, they all report an absence of correlation 
between CSF and peripheral cytokine expression.
Interestingly, recent evidence from animal models suggests 
that there is significant trafficking and recruitment of periph-
erally derived monocytes to the brain under conditions of 
psychological stress; conditions known to promote anxiety- and 
depressive-like behaviors. Upon arrival to the brain, these traf-
ficked monocytes differentiate into macrophages that promote 
inflammatory signaling and influence behavior (29). Recent 
work by our group (26) and others (25) suggests that a similar 
monocyte trafficking phenomenon might also occur in the brains 
of depressed patients. However, in remains to be determined how 
these purported monocyte–macrophages would gain access to 
the brain parenchyma.
The choroid plexus (ChP) is a highly vascularized brain struc-
ture located along the lateral, third, and fourth ventricles of the 
brain. It is composed of a continuous, single layer of cuboidal 
epithelial cells linked by tight junctions, which rests upon a basal 
lamina and delineates a connective tissue stroma containing a 
dense bed of fenestrated capillaries (30, 31). It is devoid of most 
cell types typically found in the brain parenchyma, including 
astrocytes and microglia (32). While it receives adrenergic, 
cholinergic, peptidergic, and serotonergic innervations, it does 
not contain a resident population of neurons. It is, however, home 
to its own class of resident macrophages, in addition to dendritic 
cells and other various leukocytes. Best known for the production 
of CSF, which occurs more precisely at the level of the choroidal 
epithelium, the ChP also forms part of the blood–CSF barrier 
(BCSFB) at the level of the epithelial cell tight junctions (30, 31).
Several lines of evidence have implicated the ChP in immune 
function and in inflammation. It has been demonstrated that the 
structure is capable of responding to immune modulators, as it 
constitutively expresses receptors for IL-1ß (i.e., IL1-R1), TNF-α, 
and IL-6 (33, 34), as well as cell adhesion molecules at the level 
of the choroidal epithelial cells (35). In addition, several studies 
have confirmed the ChP’s capacity to produce pro-inflammatory 
cytokines, such as IL-1ß, TNF-α, and IL-6, as well as chemokines, 
such as monocyte chemoattractant protein 1 (MCP-1), which has 
been implicated in leukocyte trafficking (30, 36, 37). Together, 
these characteristics indicate an important role for the ChP as an 
interface between peripheral and CNS inflammation.
To our knowledge, few studies have implicated the ChP 
in depression and suicide. One notable study conducted by 
Sathyanesan et al. (32) examined gene expression in several brain 
regions of mice exposed to a chronic unpredictable mild stress, a 
paradigm known to elicit depressive-like behavioral phenotypes 
in rodents. This analysis revealed increased expression of pro-
inflammatory cytokines TNF-α and IL-1ß in the ChP. More 
recently, a study conducted by Turner et al. (38) investigated gene 
expression in postmortem ChP epithelial cell layer of individuals 
having suffered from MDD. This group reported a downregula-
tion of genes associated with the TGF-ß (transforming growth 
October 2015 | Volume 6 | Article 1383
Devorak et al. Choroid plexus in depression
Frontiers in Psychiatry | www.frontiersin.org
factor ß) network. These findings might be suggestive of a poten-
tial depression-associated inflammatory response. However, it is 
clear that more work is required to better understand the potential 
involvement of the ChP in the purported peripheral and central 
inflammatory responses occurring in depression and suicide.
To this end, the present study aimed to investigate cel-
lular and molecular markers of inflammation in ChP samples 
from depressed suicides and matched sudden-death controls. 
Expression of inflammation-associated genes was measured, 
and the density and distribution of ChP macrophages assessed. 
The genes investigated included IL1ß, IL6, and TNFα, which 
encode for pro-inflammatory acute-phase proteins; IL1R1, which 
encodes the receptor of IL-1ß; IL1RN, an endogenously occur-
ring antagonist molecule of IL1-R1; IL10, an anti-inflammatory 
cytokine; MCP1, a chemokine with monocyte-attracting proper-
ties; ICAM1 (intercellular cell adhesion molecule 1) and VCAM1 
(vascular cell adhesion molecule 1), factors implicated in immune 
cell trafficking in the ChP; and IBA1, a monocyte/macrophage 
marker (13, 18, 35, 39). In addition, monocyte and/or macrophage 
trafficking through the ChP epithelium was investigated through 
quantification of Iba1-IR cells associated with the ChP epithelial 
cell layer (ECL).
Materials and Methods
samples
This study was conducted with the approval of the Douglas 
Hospital Research Ethics Board, and with informed consent from 
next-of-kin. Postmortem brain samples from depressed suicides 
(DS) and matched, psychiatrically healthy controls (CTRL) were 
obtained from the Suicide Section of the Douglas-Bell Canada 
Brain Bank (Douglas Institute). DS subjects died by suicide within 
the context of a depressive episode, whereas CTRL subjects died 
suddenly and without history of psychiatric or neurological illness. 
All DS and CTRL subjects were free of ongoing or prior immune 
or inflammatory illness. Causes of death were ascertained by the 
Quebec Coroner’s Office, and psychiatric diagnoses determined 
by psychological autopsy, as previously described (40). In brief, a 
trained interviewer conducted the Structured Clinical Interview 
for DSM-IV Psychiatric Disorders (SCID-I) with one or more 
informants of the deceased. SCID-I assessments, case reports, 
Coroner’s notes, and medical records were reviewed by a blind 
panel of clinicians to obtain a consensus diagnosis. Results of 
toxicological screening were also obtained. Tissue samples were 
dissected from the choroid plexus of the lateral ventricle. Fresh-
frozen samples were used for gene expression analyses (24 cases, 
14 controls), and fixed samples for histological analysis (5 cases, 
5 controls). Subject groups were matched for age, brain pH, RNA 
Integrity Number (RIN), and postmortem interval (PMI), defined 
as the time between death and storage of the body at the morgue 
(4°C) (Tables 1 and 2).
gene expression
Total RNA was extracted from 5 to 75  mg of fresh-frozen 
ChP tissue, depending on availability, using the RNeasy Lipid 
Tissue Mini Kit (Qiagen Inc., Mississauga, ON, Canada) 
with an additional DNase digestion performed as per the 
manufacturer’s instructions. Total RNA content was quanti-
fied using a NanoDrop 1000 spectrophotometer (NanoDrop 
Technologies, Rockland, DE, USA) and RIN determined using 
an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, 
CA, USA). Samples with RIN values below 4.5 were excluded. 
Total cDNA was synthesized from 1 μg of total RNA using 400 U 
M-MLV Reverse Transcriptase (Gibco BRL Life Technologies, 
Burlington, ON, Canada) and oligo-deoxythymidine (dT)-16, 
as per the manufacturer’s instructions. The following TaqMan 
Gene Expression Assays, labeled with FAM reporter dye, 
were used: IL1ß (TaqMan Assay ID: Hs01555410_m1), IL6 
(TaqMan Assay ID: Hs99999032_m1), IL10 (TaqMan Assay ID: 
Hs99999035_m1), IL1R1 (TaqMan Assay ID: Hs00168392_m1), 
IL1RN (TaqMan Assay ID: Hs00893626_m1), AIF1 (henceforth 
referred to as IBA1; TaqMan Assay ID: Hs00610419_g1), ICAM1 
(TaqMan Assay ID: Hs00164932_m1), VCAM1 (TaqMan 
Assay ID: Hs01003372_m1), TNF (henceforth referred to as 
TNFα; TaqMan Assay ID: Hs00174128_m1), MCP1 (TaqMan 
Assay ID: Hs00234140_m1), and POLR2A (Taqman Assay ID: 
Hs00172187_m1). An ACTB TaqMan Gene Expression Assay 
TaBle 1 | subject information: gene expression cohort.
Ds cTrl
n 24 14
Male/female 20/4 11/3
Age (years) 44 ± 2.8 45 ± 5.8
PMI (h) 22.5 ± 3.0 22.5 ± 5.8
Brain pH 6.6 ± 0.1 6.5 ± 0.1
RIN 7.2 ± 0.1 7.3 ± 0.2
Axis 1 disorders MDD (21); DNOS (3) Nil (14)
Cause of death Hanging (16)
Intoxication (5)
Drowning (2)
Jumping (1)
Car accident (7)
Unknown (2)
Medical intoxication (1)
Cardiovascular: cardiac arrest (2)
Cardiac arrhythmia (1)
Myocardial infarction (1)
Groups are statistically similar with respect to age, postmortem interval (PMI), brain pH, 
and RNA integrity number (RIN). Values are reported as ± SEM.
DS, depressed suicide; CTRL, control; MDD, major depressive disorder; DNOS, 
depressive disorder not otherwise specified.
TaBle 2 | subject information: histology cohort.
Ds cTrl
n 5 5
Male/female 3/2 5/0
Age (years) 45 ± 11.4 50 ± 11.0
PMI (h) 22.9 ± 13.5 13.4 ± 8.3
Brain pH 6.4 ± 0.2 6.8 ± 0.1
Axis 1 disorders MDD (5) Nil (5)
Cause of death Hanging (4)
Intoxication (1)
Car accident (2)
Other accident (1)
Cardiac arrest (1)
Unknown (1)
Groups are statistically similar with respect to age, postmortem interval (PMI), and brain 
pH. Values are reported as ± SEM.
DS, depressed suicide; CTRL, control; MDD, major depressive disorder; DNOS, 
depressive disorder not otherwise specified.
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(ID: 4310881E) labeled with VIC reporter dye was also used. Real-
time PCR (RT–PCR) reactions were run in quintuplicate with 2 μl 
of cDNA, 0.6 μl of 20× TaqMan Gene Expression Assay specific 
to each quantified gene, 6 μl PerfeCTa qPCR Fast Mix (Quanta 
BioSciences Inc., Gaithersburg, MD, USA) or 6 μl TaqMan Fast 
Advanced Master Mix (Applied Biosystems, Foster City, CA, 
USA), and water (milliQ). A standard curve of pooled cDNA 
from all subjects was used. However, when cytokine expression 
was too low, a standard curve of cDNA from B-lymphocytes was 
utilized instead. All samples were analyzed with an ABI PRISM 
7900HT Sequence Detection System (Applied Biosytems, Foster 
City, CA, USA) as per the manufacturer’s instructions using a 
standard thermal cycling profile. The cycle threshold (CT) values 
of replicates were pooled to obtain the mean value per subject. 
Samples with CT standard deviation values above 0.3 were 
excluded from analysis to avoid excessive variability amongst 
replicates. Absolute quantification of expression analysis of each 
gene was performed with housekeeping genes POLR2A and 
ACTB as endogenous controls and analyzed using SDS software 
version 2.4 (Applied Biosystems, Foster City, CA, USA).
iba-1 immunohistochemistry
Fixed samples were dehydrated through a graded series of 
ethanol solutions, cleared in xylene, and embedded in paraffin. 
Paraffin-embedded tissue was then cut into 40 μm-thick serial 
sections on a microtome and collected on slides for Iba-1 immu-
nohistochemistry, performed as previously described (26). In 
brief, tissue sections underwent antigen retrieval by Proteinase 
K (20 μg/ml) followed by an incubation in 3% H2O2. Sections 
were then incubated in a 2% normal goat serum blocking solu-
tion overnight before being incubated 24 h in the same blocking 
solution to which the anti-Iba-1 polyclonal rabbit antibody was 
added (1:1000; WAKO Chemicals USA, Inc., Richmond, VA, 
USA). This was followed by a 2 h incubation in blocking solution 
with a biotinylated goat anti-rabbit secondary antibody (1:1000; 
Vector Laboratories Inc., Burlington, ON, Canada). Labeling was 
revealed with a diaminobenzidine kit (Vector Laboratories Inc., 
Burlington, ON, Canada), and samples were counterstained with 
cresyl violet to better differentiate ChP compartments (Figure 1).
Quantitative assessment of epithelial layer-
associated iba1-immunoreactive cells
To estimate ECL-associated Iba1-immunoreactive (-IR) cell 
densities, a counting area comprising ECL was randomly 
selected within a subset of Iba1-processed tissue sections with 
a Zeiss Axio Imager.M2 microscope equipped with a motorized 
stage and an AxioCam MRc camera. Counting was limited to 
ECL that was clearly discernible within viewing frames at 10× 
magnification. Discrete ECL contours were traced using Stereo 
Investigator software (MBF Bioscience, Williston, VT, USA) and 
contour areas were calculated using Neurolucida software (MBF 
Bioscience). 3D virtual tissues encompassing these contours 
were taken at 40× magnification using Stereo Investigator soft-
ware. Iba1-IR cells were then quantified using the cell counter 
plug-in feature of Fiji, an open access software (ImageJ; NIH). 
Only cells that were located within, or that came into direct 
contact with, the ECL contours were counted (Figure 1 inset). 
Given the uneven thickness of the tissue sections following 
Iba-1 immunohistochemical processing, counting volume was 
calculated for each discrete contour within a given tissue section, 
by multiplying the area of each respective contour by the number 
of z-stacks in which the counting was performed. Density was 
calculated by dividing the total number of Iba1-IR cells by the 
total volume of counting contours for each subject. These analy-
ses were performed by an investigator (JD) who remained blind 
to subject groups.
statistical analyses
All statistical analyses were performed, and all graphs were 
produced, using GraphPad Prism 6 (GraphPad Software Inc., 
La Jolla, CA, USA), unless otherwise noted. All measurements 
were expressed as mean ±  SEM, and a p ≤  0.05 threshold was 
used to determine statistical significance, unless otherwise noted. 
p-Values exceeding this significance threshold but not exceeding 
an alpha level of 0.10 were considered statistical trends. Normality 
was assessed using Shapiro–Wilk tests, and outlier detection was 
performed using the 3.0IQR method in IBM SPSS Statistics 20 
(Statistical Product and Service Solutions, Chicago, IL, USA). 
For parametric data, two-tailed t-tests were used for two-group 
comparisons, and one-way analyses of variance (ANOVAs) were 
employed for three-group comparisons. Post  hoc analyses for 
parametric 3-group comparisons were conducted using Tukey’s 
HSD test. When data were non-parametric, two-tailed Mann–
Whitney U or Kruskal–Wallis tests were used for two-group 
and three-group comparisons, respectively. Post hoc analyses for 
non-parametric three-group comparisons were conducted using 
Mann–Whitney U-tests with an adjusted alpha level of p = 0.0167. 
Pearson or Spearman correlations were performed on measured 
variables of normal and non-normal distributions, respectively, 
to examine the influence of potential confounding factors. When 
significant correlations were detected, analysis of covariance 
FigUre 1 | iba-1 immunostained choroid plexus with cresyl violet 
counterstain at 10× magnification. Star denotes connective tissue 
stroma; yellow arrow indicates epithelial cell layer; green arrow points to 
blood vessel. Inset: 40× magnification. Pink arrows show Iba1-IR cells 
associated with the stroma or the epithelial cell layer.
FigUre 2 | absolute expression of IL1β rna transcript in the choroid 
plexus of psychiatrically healthy controls (cTrl) and depressed 
suicides (Ds). A significant downregulation in IL1β expression was observed 
in DS as compared to CTRL subjects; p = 0.013. All values are reported as 
the mean ratio of IL1β expression to the geometric mean expression of 
endogenous control genes ACTB and POLR2A.
FigUre 3 | absolute rna transcript expression of blood–csF barrier-associated molecules in the choroid plexus of psychiatrically healthy controls 
(cTrl) and depressed suicides (Ds). (a) A significant downregulation in expression of ICAM1 was observed in DS as compared to CTRL subjects; p = 0.002. 
(B) No significant differences in MCP1 transcript expression were found between groups; p > 0.05. (c) Average VCAM1 transcript expression was found to be 
similar between groups; p > 0.05. All values are reported as the mean ratio of expression of probe of interest to the geometric mean expression of endogenous 
control genes ACTB and POLR2A.
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(ANCOVA) was performed. Non-parametric data sets that 
positively correlated with confounding factors were transformed 
using a log10 transformation in order to perform ANCOVA.
results
cytokine, cell adhesion Molecule, and 
chemoattractant gene expression
IL1ß mRNA transcript expression was significantly downregu-
lated in DS subjects compared to CTRLs (U(12, 18) = 50, p = 0.013) 
(Figure 2). TNFα, IL10, and IL6 transcript expressions were also 
decreased in DS compared to CTRLs; however, these differences 
did not reach statistical significance. Conversely, IL1R1 and 
IL1RN gene expression were elevated in DS subjects compared 
to CTRLs, though these differences did not reach statistical 
significance either.
ICAM1 gene expression was significantly downregulated in DS 
compared to CTRL subjects (t(20) = 3.647, p = 0.002) (Figure 3A), 
but there were no significant differences in VCAM1 or MCP1 
transcript expression between groups (Figures 3B,C).
Three-group comparisons were performed to assess the poten-
tial effects of antidepressant treatment (ADT) on the expression 
of the investigated genes, as ADT has been reported to modulate 
expression levels of peripheral pro-inflammatory cytokines in 
depressed patients [(41, 42); for a review, see Ref. (43)]. DS subjects 
were therefore further divided into those receiving ADT around 
time of death (DS + ADT) and those who were not (DS). ANOVA 
revealed ICAM1 to be differentially expressed amongst groups (F(2, 
19) = 4.376, p = 0.027). Subsequent post hoc pairwise comparisons 
revealed that only CTRL and DS differed significantly (p = 0.026), 
with DS expressing lower transcript levels than controls. No 
significant differences were detected between DS + ADT and DS 
subjects, or between DS + ADT and CTRL subjects (not shown). 
Consequently, ADT was not considered a significant confounding 
factor with respect to ICAM1 transcript expression.
iBa1 gene expression and cell Density
IBA1 mRNA transcript expression was significantly downregu-
lated in DS compared to CTRL subjects (t(20) = 2.253, p = 0.032) 
(Figure 4A). However, total densities of ECL-associated Iba1- 
IR cells did not differ significantly between the two groups 
(Figure 4B).
Potential confounding Factors
As males and female have been previously reported to present 
unique cytokine profiles in the context of suicide (21), potential 
sex differences were investigated by employing two-group com-
parisons for each gene investigated. IL10 transcript expression 
was found to be significantly downregulated in female subjects as 
compared to males (U(5, 27) = 20, p = 0.011) (Figure 5A). As exclu-
sion of female subjects had no impact on IL10 analyses, female 
subjects were included in these analyses to increase statistical 
power. While no additional significant sex-based differences were 
FigUre 5 | sex differences in choroid plexus cytokine gene expression. (a) Absolute expression of IL10 RNA transcript in male (M) and female (F) subjects. 
Females expressed significantly less IL10 than male subjects; p = 0.011. (B) Absolute expression of IL1β RNA transcript in male and female subjects. A trend 
toward decreased IL1β was detected in female versus male subjects, p = 0.075. (c) Absolute expression of IL1RN RNA transcript in male and female subjects. A 
trend toward decreased IL1RN was detected in female versus male subjects, p = 0.053. All values are reported as the mean ratio of expression of probe of interest 
to the geometric mean expression of endogenous control genes ACTB and POLR2A. #denotes statistical trend, 0.05 < p ≤ 0.10.
FigUre 4 | IBA1 gene expression and immunohistochemical distribution. (a) Absolute expression of IBA1 RNA transcript in the choroid plexus of 
psychiatrically healthy controls (CTRL) and depressed suicides (DS). DS expressed significantly less IBA1 than CTRL subjects; p = 0.032. Values are reported as the 
mean ratio of IBA1 expression to the geometric mean expression of endogenous control genes ACTB and POLR2A. (B) Quantification of Iba1-IR cells in the choroid 
plexus epithelial layer of CTRL and DS. No significant difference in epithelial layer Iba1-IR cell number was observed between groups; p > 0.10.
October 2015 | Volume 6 | Article 1386
Devorak et al. Choroid plexus in depression
Frontiers in Psychiatry | www.frontiersin.org
detected, two statistical trends were revealed: decreased IL1ß (U5, 
26) = 32, p = 0.075) and IL1RN (U(3, 18) = 8, p = 0.053) transcript 
expression in females as compared to males (Figures 5B,C).
The potential confounding effect of substance dependence 
(SD) on gene expression was also assessed by dividing DS sub-
jects into those with (DS + SD) and without comorbid SD (DS) 
and then employing three-group comparisons for each gene of 
interest. ANOVA revealed IBA1 to be differentially expressed 
amongst groups (F(2, 28) = 3.860, p = 0.033). Subsequent post hoc 
pairwise comparisons revealed that only CTRL and DS differed 
significantly (p =  0.031), with DS expressing lower transcript 
levels than controls. No significant differences were detected 
between DS +  SD and DS subjects, or between DS +  SD and 
CTRL subjects (not shown). Consequently, substance depend-
ence was not considered a significant confounding factor with 
respect to IBA1 transcript expression.
Multiple correlations were performed to assess the potentially 
confounding effects of age, PMI, and tissue pH on gene expression 
and Iba1-IR cell density. Significant positive correlations between 
IL6 mRNA transcript expression and age (ρ = 0.361, p = 0.050) and 
between IL1R1 mRNA transcript expression and pH (ρ = 0.556, 
p  =  0.002) were detected. Analysis of covariance (ANCOVA) 
revealed no significant difference between DS and CTRL IL6 
expression when controlling for the effect of age, nor any additional 
significant group comparisons of IL6 expression after controlling for 
the effect of age. In addition, ANCOVA revealed no significant dif-
ference between DS and CTRL IL1R1 expression when controlling 
for the effect of pH, and no further significant group comparisons 
of IL1R1 expression after controlling for the effect of pH.
Discussion
To the best of our knowledge, the present study is the first to 
specifically investigate inflammatory cells and molecules in the 
human ChP in the context of depression and suicide. While we 
found no direct cellular or molecular evidence of inflammation 
in the ChP, our findings may provide an indirect indication of a 
central and/or peripheral inflammatory response.
Expression of IL1ß, a pro-inflammatory cytokine, was decreased 
in the ChP samples from depressed suicides. This finding contrib-
utes to a heterogeneous body of literature concerning peripheral 
and central IL1ß regulation in human studies of depression and/
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or suicide. While some postmortem studies have reported both 
increased mRNA and/or protein expression of this cytokine in 
prefrontal cortex of depressed patients and/or suicide completers 
(21, 22), others have reported unaltered expression of this gene in 
anterior cingulate cortex (26). Studies in clinical populations have 
suggested elevated levels of IL-1ß in blood (44) and CSF (27) of 
depressed patients, however unaltered levels of IL-1ß have also 
been reported in depressed patients and/or suicide attempters (28). 
Interestingly, the present finding contrasts with that of Sathyanesan 
et al. (32), who reported increased IL1ß gene expression in the lateral 
ChP of rats exposed to a chronic unpredictable stress paradigm, a 
well-established animal model of depression.
Interestingly, in addition to IL1ß expression, IBA1 gene expres-
sion was also found to be significantly downregulated in depressed 
suicides. Taken together, these findings could reflect decreased 
macrophage numbers in the ChP, as ChP macrophages have previ-
ously been reported to express IL-1ß (45). However, the present 
study also revealed unaltered density of ChP ECL-associated 
Iba1-IR cells, suggesting that any potential decrease in IBA1 expres-
sion would be localized to a ChP compartment other than the ECL.
We can further speculate that the observed decrease in ChP 
IL1ß gene expression in the present study might be indicative of 
a compensatory mechanism to attenuate the effects of chronically 
altered central and/or peripheral IL1ß expression. One possibil-
ity is that altered cerebral IL1ß production elicited the proposed 
compensatory mechanism. Indeed, increased IL-1ß gene and 
protein expression in the prefrontal cortex (Brodmann areas 8 and 
10) of suicides has been reported (22). It is possible that elevated 
IL-1ß derived from resident brain cells reaches the ChP by way 
of a reverse nexus pathway described by Johanson et al. (46): after 
release into the brain interstitial fluid (ISF), IL-1ß would diffuse 
across a transependymal concentration gradient into the CSF, 
ultimately reaching the ChP by bulk flow of CSF. To counteract 
the increased activation of pro-inflammatory signaling pathways 
in the brain by increased levels of centrally derived IL-1ß, the 
ChP might function to reduce the amount of CSF-destined 
IL-1ß it generates, thereby curtailing the total amount of IL-1ß 
accessing the brain parenchyma. Indeed, ChP epithelial cells are 
known to produce and secrete cytokines and other intermediate 
messenger molecules, such as prostaglandins, into the CSF in 
response to activation by other cytokines (34). Existence of such 
a phenomenon could help explain reports of unaltered CSF IL-1ß 
concentrations in depressed patients and suicide attempters 
[e.g., Ref. (28)]. Alternatively, the ChP might work to attenuate 
the pro-inflammatory effects that elevated cerebral IL-1ß levels 
might have on the periphery, via the structure’s extensive network 
of fenestrated capillaries, by reducing the amount of IL-1ß that 
is generated by cells associated with the vasculature, such as 
perivascular macrophages and pericytes. Both of these cell types 
are known to produce and secrete cytokines in response to their 
activation by other cytokines (34).
Alternatively, it is possible that the proposed compensatory 
mechanism arose as a result of altered levels of peripherally 
derived IL-1ß. Originally reported by Maes et al. (14), elevated 
plasma and serum IL-1ß protein levels have been reported by 
several independent groups [for reviews, see Ref. (17–19)]. 
Cytokines secreted into the bloodstream during infection and 
systemic inflammation are known to activate cells in the ChP, 
such as epithelial cells, perivascular macrophages, and pericytes, 
thereby stimulating production and secretion of cytokines into 
the CSF. These molecules can then infiltrate the brain ISF and 
activate resident immune cells (34). In fact, it has been demon-
strated that sub-chronic peripheral IL-1ß administration results 
in increased IL1ß mRNA expression in discrete cortical and 
subcortical areas (47). In the present case, chronically elevated 
levels of peripherally-derived blood-borne IL-1ß, accessing the 
ChP by way of the structure’s fenestrated capillaries, might trigger 
a compensatory decrease in ChP IL1ß production. This would 
curtail the amount of ChP-derived IL-1ß (or other cytokines and 
intermediate messenger molecules) that could feed back into the 
bloodstream or gain access to the CSF by an as-of-yet unknown 
BCSFB transversal mechanism, or both; moreover, it could curtail 
the ChP’s production of IL-1ß destined for the CSF.
Interestingly, the present findings collectively suggest activa-
tion of a compensatory (anti)inflammatory reflex system (CIRS), 
as has been described by Maes (44) and Maes et al. (48). The CIRS 
is a constellation of regulatory mechanisms, which attenuate the 
inflammatory response observed in clinical depression, and which 
are often accompanied by signs of immunosuppression. These 
regulatory mechanisms include, but are not limited to, increased 
production of: interleukin-1 receptor antagonist (IL-1Ra), which 
inhibits the function of IL-1ß; IL-10, a negative immunoregulatory 
cytokine; and glucocorticoids and certain acute-phase proteins, 
which can act as immunosuppressors. While we report no elevation 
in expression of the genes encoding IL-1Ra (IL1RN) or IL-10 at the 
level of the ChP, we do report gene expression profiles suggestive of 
CIRS-associated immunosuppression. For example, the observed 
decrease in IL1ß expression and unaltered IL6 expression might be 
indicative of the immunosuppressive actions of glucocorticoids, 
which are known to inhibit production of IL-1ß and IL-6.
Furthermore, it has been hypothesized that the number and 
function of immune cells, such as monocytes and T cells, might 
also be negatively regulated by the CIRS (44, 48). IDO activation 
and reduction of plasma tryptophan levels are thought to be CIRS 
regulatory mechanisms, and IDO-induced tryptophan reduction 
and increased tryptophan catabolite (TRYCAT) formation have 
been shown to attenuate T cell activation and proliferation (48), 
which could in turn impact monocyte/macrophage number and 
function. The presently observed decrease in ChP IBA1 expres-
sion might therefore be indicative of a CIRS-associated decrease 
in number of ChP macrophages. Furthermore, decreased IBA1 
expression in conjunction with decreased IL1ß expression might 
be indicative of a CIRS-associated decline in function of ChP 
monocytes and/or macrophages.
The present results also indicate a downregulation in ChP 
ICAM1 gene expression in depressed suicides. As ICAM-1 is 
expressed by choroid epithelial cells and is thought to support 
immune cell trafficking in the ChP (35, 49), this finding might 
be an indication of attenuated immune cell trafficking through 
the BCSFB in depression and suicide. ICAM-1 in the choroidal 
epithelium is also known to be upregulated in response to acute 
pro-inflammatory molecule exposure in vitro (49). It is possible 
that the presently observed downregulation of ICAM1 expres-
sion in the choroid plexus might represent a compensatory 
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mechanism that functions to counteract (chronically) increased 
activation of pro-inflammatory signaling pathways elicited 
by chronically elevated cytokine levels frequently observed in 
depressed patients. An attenuation of immune cell trafficking into 
or out of the structure by way of the BCSFB could consequently 
curtail central and/or peripheral pro-inflammatory signaling. 
Interestingly, the observed decrease in ChP IBA1 expression in 
depressed suicides could reflect such an attenuation of immune 
cell trafficking into the ChP – more specifically, that of monocytes 
and/or macrophages. In addition, the observed unaltered density 
of ChP ECL-associated Iba1-IR cells in DS subjects could further 
suggest a compensatory attenuation of monocytes and/or mac-
rophages trafficking into the ChP.
Several confounding factors may have influenced the present 
results, and these accordingly merit discussion. One potential 
confounding factor in both the gene expression and histological 
analyses was the heterogeneity of the tissue samples. Most tissues 
were dissected, with a reasonable degree of certainty, from the 
choroid plexus of the lateral ventricle. However, tissue was not 
consistently sampled from the same region of the lateral ventricle 
ChP, often due to varying tissue availability. While it is unclear 
whether regional differences exist within the human ChP, by vir-
tue of which inconsistent tissue sampling could affect the present 
analyses, the possibility cannot be ruled out.
A second potentially confounding factor, for gene expression 
analyses exclusively, was the heterogeneity of the depressed 
suicide group. Several independent groups have demonstrated 
that differing peripheral cytokine profiles exist among MDD 
subtypes, including melancholic, atypical, and treatment resistant 
[e.g., see Ref. (50–53)]. Furthermore, different stages of depres-
sion have been shown to present unique cytokine expression 
profiles (51). The present DS cohort contained several subjects 
who did not have a diagnosis of MDD, but rather a depressive 
disorder not otherwise specified. In addition, depression subtype 
and staging were unknown for these subjects, as this retrospec-
tive data was not available. Another confounding factor, for gene 
expression analyses exclusively, was the presence of considerable 
quantities of blood in the frozen ChP tissue. As it was impossible 
to remove the blood from the ChP tissue, RNA was extracted, 
and cDNA was synthesized, from ChP tissue together with the 
blood it contained. Consequently, the gene expression analyses 
conducted in this study reflect ChP-derived gene transcripts as 
well as peripherally-derived transcripts of unknown quantities.
Lastly, in addition to the aforementioned experimental con-
founds, the present study presents other limitations such as small 
sample size and lack of retrospective data for both CTRL and DS 
cohorts. Small sample size was due to the limited number of ChP 
tissue samples meeting the criteria for our study, in conjunction 
with the exclusion criteria employed in analyzing replicates 
for each probe of interest, in the gene expression experiments. 
Certain retrospective data, such as smoking, BMI, and disease 
subtype and staging, were often unavailable.
In conclusion, this exploratory study is the first to provide 
evidence for altered gene expression profiles of pro-inflammatory 
cytokines, immune cells, and factors implicated in immune cell 
trafficking, in the choroid plexus of depressed suicides. IL1ß, 
ICAM1, and IBA1 gene expression were all found to be down-
regulated in depressed suicides. Together, these findings are sug-
gestive of a compensatory mechanism at the level of the ChP that 
might function to attenuate a chronically activated inflammatory 
response. While these findings do not provide direct evidence of 
ChP inflammation in the context of depression and suicide, the 
altered gene expression profiles described herein may indirectly 
indicate pro-inflammatory phenomena occurring peripherally 
and/or centrally. Overall, these findings provide further evidence 
that neuroimmune processes are implicated in depression and 
suicide.
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